JP2019518452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518452A5 JP2019518452A5 JP2018560847A JP2018560847A JP2019518452A5 JP 2019518452 A5 JP2019518452 A5 JP 2019518452A5 JP 2018560847 A JP2018560847 A JP 2018560847A JP 2018560847 A JP2018560847 A JP 2018560847A JP 2019518452 A5 JP2019518452 A5 JP 2019518452A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- marker
- cancer
- antibody
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims 5
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims 5
- 101001051272 Homo sapiens Layilin Proteins 0.000 claims 5
- 101001057135 Homo sapiens Melanoma-associated antigen H1 Proteins 0.000 claims 5
- 102100024621 Layilin Human genes 0.000 claims 5
- 102100027256 Melanoma-associated antigen H1 Human genes 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010064390 Tumour invasion Diseases 0.000 claims 2
- 230000009400 cancer invasion Effects 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102100024209 CD177 antigen Human genes 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 claims 1
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 claims 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 1
- 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- -1 PDL-2 Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 102100025795 Signal-regulatory protein gamma Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000005735 apoptotic response Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000002074 deregulated effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 claims 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096086A JP2023113918A (ja) | 2016-05-16 | 2023-06-12 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| JP2025132766A JP2025172069A (ja) | 2016-05-16 | 2025-08-07 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169791.7 | 2016-05-16 | ||
| EP16169791 | 2016-05-16 | ||
| EP16198724.3 | 2016-11-14 | ||
| EP16198724 | 2016-11-14 | ||
| PCT/EP2017/061642 WO2017198631A1 (en) | 2016-05-16 | 2017-05-15 | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096086A Division JP2023113918A (ja) | 2016-05-16 | 2023-06-12 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518452A JP2019518452A (ja) | 2019-07-04 |
| JP2019518452A5 true JP2019518452A5 (enExample) | 2020-06-25 |
| JP7358047B2 JP7358047B2 (ja) | 2023-10-10 |
Family
ID=58772864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560847A Active JP7358047B2 (ja) | 2016-05-16 | 2017-05-15 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| JP2023096086A Pending JP2023113918A (ja) | 2016-05-16 | 2023-06-12 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| JP2025132766A Pending JP2025172069A (ja) | 2016-05-16 | 2025-08-07 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096086A Pending JP2023113918A (ja) | 2016-05-16 | 2023-06-12 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| JP2025132766A Pending JP2025172069A (ja) | 2016-05-16 | 2025-08-07 | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190391152A1 (enExample) |
| EP (2) | EP3458473B8 (enExample) |
| JP (3) | JP7358047B2 (enExample) |
| KR (1) | KR102623927B1 (enExample) |
| CN (1) | CN109715653A (enExample) |
| AU (1) | AU2017266686B2 (enExample) |
| ES (1) | ES2922525T3 (enExample) |
| MX (2) | MX395142B (enExample) |
| WO (1) | WO2017198631A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715653A (zh) | 2016-05-16 | 2019-05-03 | 驰科迈博有限责任公司 | 肿瘤浸润调节性t细胞中被选择性地去调节的标志物 |
| PT3431105T (pt) | 2017-03-29 | 2020-03-11 | Shionogi & Co | Composição medicinal para tratamento de cancro |
| EP3841123A2 (en) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anti-tigit antibodies |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| IL263394A (en) * | 2018-11-29 | 2020-05-31 | Amit Ido | Methods of activating dysfunctional immune cells and treatment of cancer |
| BR112021011431A2 (pt) * | 2018-12-27 | 2021-11-23 | Univ Osaka | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit |
| WO2020163876A1 (en) * | 2019-02-08 | 2020-08-13 | The Regents Of The University Of California | Compositions and methods involving layilin |
| CN110187107A (zh) * | 2019-04-26 | 2019-08-30 | 温州医科大学 | 一种基于肿瘤组织浸润免疫细胞特征建立的结直肠癌预后评估装置及方法 |
| JP2023514441A (ja) * | 2020-02-20 | 2023-04-05 | アンスティテュ・クリー | 機能性疾患特異的制御性ｔ細胞を同定する方法 |
| JP2023515981A (ja) * | 2020-02-26 | 2023-04-17 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンαアミド化モノオキシゲナーゼ（ＰＡＭ）を決定する方法および診断目的でのその使用 |
| BR112022019708A2 (pt) * | 2020-04-01 | 2022-12-20 | Xilio Dev Inc | Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| CN113933508A (zh) * | 2020-07-13 | 2022-01-14 | 上海吉凯基因医学科技股份有限公司 | 人batf基因的用途及相关产品 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| PE20240638A1 (es) | 2021-07-14 | 2024-03-27 | Genentech Inc | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso |
| TWI920354B (zh) | 2021-07-27 | 2026-04-01 | 美商艾伯維有限公司 | 抗ｃｃｒ８抗體 |
| CN114381528B (zh) * | 2022-02-14 | 2024-06-28 | 天津市泌尿外科研究所 | Mettl7a基因及其表达产物在诊断和治疗肿瘤中的用途 |
| KR102492241B1 (ko) * | 2022-02-25 | 2023-01-30 | 전남대학교산학협력단 | Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도 |
| KR20240113400A (ko) * | 2023-01-11 | 2024-07-22 | 한국과학기술원 | 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| CN117079710B (zh) * | 2023-08-18 | 2024-05-31 | 上海爱谱蒂康生物科技有限公司 | 生物标志物及其在预测和/或诊断utuc肌肉浸润中的应用 |
| CN117587014B (zh) * | 2023-11-24 | 2025-01-24 | 上海恩凯细胞技术有限公司 | 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| CN117625792B (zh) * | 2024-01-23 | 2024-04-16 | 杭州华得森生物技术有限公司 | 用于胃癌诊断和预后判断的生物标志物及其应用 |
| CN118064595B (zh) * | 2024-04-17 | 2024-08-02 | 中山大学附属第六医院 | 一种预测结直肠癌肝转移的生物标志物及其应用 |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075A (en) | 1847-04-17 | Improvement in cultivators | ||
| US109A (en) | 1836-12-15 | Erawijtg | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| AU8669598A (en) * | 1997-07-29 | 1999-02-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chemokine receptor ccr8 dna and uses thereof |
| AR016681A1 (es) * | 1997-11-13 | 2001-07-25 | Schering Corp | Deplecion de celulas th2; composiciones; metodos |
| CA2513143A1 (en) * | 2002-07-01 | 2004-01-08 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| US20120135415A1 (en) * | 2002-11-15 | 2012-05-31 | Morehouse School Of Medicine | Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| JP2008072939A (ja) * | 2006-09-21 | 2008-04-03 | Fujifilm Corp | 多発性骨髄腫の検出方法および抑制方法 |
| US20100292303A1 (en) * | 2007-07-20 | 2010-11-18 | Birrer Michael J | Gene expression profile for predicting ovarian cancer patient survival |
| WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| WO2013131010A2 (en) * | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| WO2015017537A2 (en) * | 2013-07-30 | 2015-02-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Colorectal cancer recurrence gene expression signature |
| CN109715653A (zh) | 2016-05-16 | 2019-05-03 | 驰科迈博有限责任公司 | 肿瘤浸润调节性t细胞中被选择性地去调节的标志物 |
-
2017
- 2017-05-15 CN CN201780043484.XA patent/CN109715653A/zh active Pending
- 2017-05-15 US US16/301,805 patent/US20190391152A1/en not_active Abandoned
- 2017-05-15 KR KR1020187036507A patent/KR102623927B1/ko active Active
- 2017-05-15 AU AU2017266686A patent/AU2017266686B2/en active Active
- 2017-05-15 EP EP17725914.0A patent/EP3458473B8/en active Active
- 2017-05-15 MX MX2018013952A patent/MX395142B/es unknown
- 2017-05-15 EP EP22159825.3A patent/EP4092045A1/en active Pending
- 2017-05-15 JP JP2018560847A patent/JP7358047B2/ja active Active
- 2017-05-15 WO PCT/EP2017/061642 patent/WO2017198631A1/en not_active Ceased
- 2017-05-15 ES ES17725914T patent/ES2922525T3/es active Active
-
2018
- 2018-11-14 MX MX2022010703A patent/MX2022010703A/es unknown
-
2023
- 2023-04-05 US US18/295,965 patent/US12247982B2/en active Active
- 2023-06-12 JP JP2023096086A patent/JP2023113918A/ja active Pending
-
2025
- 2025-01-27 US US19/037,818 patent/US20260056201A9/en active Pending
- 2025-08-07 JP JP2025132766A patent/JP2025172069A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ascierto et al. | Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients | |
| Qi et al. | The significance of liquid biopsy in pancreatic cancer | |
| Lee et al. | High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients | |
| Decock et al. | Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings | |
| Zhang et al. | Genotyping of–765G> C in COX-2 gene based on MNPs and dual-color fluorescence hybridization and its association with risk of gastric cancer in northern Jiangsu of China | |
| JP2014503180A5 (enExample) | ||
| KR101801980B1 (ko) | 중추신경계 림프종 진단용 조성물 및 이를 이용한 중추신경계 림프종 진단 키트 | |
| KR20170072685A (ko) | 삼중음성유방암의 아형 분류 방법 | |
| Ek et al. | From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies | |
| Li et al. | The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas | |
| ES2906203T3 (es) | Variante de CIP2A novedosa y usos de la misma | |
| Su et al. | KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer | |
| JPWO2017033905A1 (ja) | Ｏｃｌｎ−ａｒｈｇａｐ２６遺伝子の検出方法 | |
| US20160091485A1 (en) | Markers for ezh2 inhibitors | |
| CN116888278A (zh) | 分析癌症基质中免疫浸润以预测临床转归的方法和组合物 | |
| Tsukamoto et al. | Recurrence of Lung Adenocarcinoma After an Interval of 15 Years Revealed by Demonstration of the Same Type of EML4–ALK Fusion Gene | |
| KR20120060442A (ko) | 위암 진단용 마커로서 ｔｆｆ2의 용도 | |
| WO2009150491A2 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy | |
| JP2008283945A (ja) | 肝癌検出用マーカー | |
| JP2009523004A5 (enExample) | ||
| JP2005504830A5 (enExample) | ||
| JP2008535855A5 (enExample) | ||
| WO2023244680A3 (en) | Reagents and methods for cell identification and characterization | |
| KR20200038659A (ko) | 대식세포 특이적 바이오마커 패널 및 이의 용도 | |
| JP4330372B2 (ja) | 胃癌由来の転移癌細胞の検出方法 |